Online Store: Webinar Recordings
Main Storefront

ISCT Webinar 2019: Gaps in Knowledge of hPL

Item Options
Sign in for your pricing!
Price: $0.00
Quantity: *

ISCT Webinar

Gaps in the Knowledge of Human Platelet Lysate as a Cell Culture Supplement for Cell Therapy

Sponsored by ISCT

Event Date
Wednesday, July 17, 2019
09:00 PDT, 12:00 EDT, 18:00 CET


Joint Publication from ISCT and AABB Now Available Online inCytotherapy

Download the Paper (Open Access)


Lizette Caballero
ISCT Co-Chair, ISCT-AABB Joint Working Group
Senior Supervisor
UCSF Medical Center


Karen Bieback, PhD
Institute for Transfusion Medicine and Immunology
Heidelberg University

Jacques Galipeau, MD
Don and Marilyn Anderson Professor in Oncology
Department of Medicine
University of Wisconsin in Madison

Gaps in the Knowledge of Human Platelet Lysate as a Cell Culture Supplement for Cell Therapy: Results from the joint working group from ISCT and AABB

The talk will present the results of the joint working group in identifying gaps in knowledge in:

  • hPL as an alternative to FBS
  • hPL production
  • Pathogen reduction treatment of hPL
Manufacturing Mesenchymal Stromal Cells (MSCs) for Clinical Applications: A Survey of Good Manufacturing Practices at U.S. Academic Centers with emphasis on culture methods.

Survey responses reported herein offer insight into the current best practices used to manufacture MSC-based products in the U.S. and how these practices, including use of hPL, may impact product quality and potency.
About the Webinar

Fetal bovine serum (FBS) is used as a growth supplement in a wide range of cell culture applications for cell-based research and therapy. However, as a xenogenic product, FBS can potentially transmit prions and adventitious viruses as well as induce undesirable immunological reactions. In addition, the use of bovine fetuses for FBS production raises concerns as society looks for ways to replace animal testing and reduce the use of animal products for scientific purposes − in particular for the manufacture of clinical products intended for human use. Until chemically-defined media are available for these purposes, human platelet lysate (hPL) has been introduced as an attractive alternative for replacing FBS as a cell culture supplement. hPL is a human product that can be produced from outdated platelets avoiding ethical, medical and animal welfare concerns. An increasing number of studies demonstrate that hPL can promote cell growth similarly or even better than FBS in specific cell types. Due to increasing interest in hPL the International Society for Cell & Gene Therapy (ISCT) and AABB established a joint working group to address its potential. With this webinar, we aim to present an overview of hPL identifying the gaps in information on how hPL is produced and tested and the barriers to its translational use in the production of clinical grade cell therapy products.

Learning Objectives:

  • Classify and evaluate current gaps in knowledge of hPL as cell culture supplement
  • Discuss and propose recommendations for standardization of hPL production


© 2020 ISCT. All rights reserved. 
ISCT, INTERNATIONAL SOCIETY FOR CELLULAR THERAPY and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy